Synergistic action of adenosine and fMet-Leu-Phe in raising cAMP content of purified human monocytes.
The content of cAMP was measured in monocytes treated with fMet-Leu-Phe and adenosine, either singly or in combination. Adenosine caused a small and variable rise in cAMP, which was considerably less than that caused by fMet-Leu-Phe. The rise induced by peptide plus adenosine was twice the sum of the increases caused by each agent alone. An inhibitor of phosphodiesterase also enhanced the adenosine-induced rise in cAMP. The data suggest that the increase in cAMP by adenosine-induced cyclase activation is limited by the activity of phosphodiesterase, and that the latter can be inhibited by fMet-Leu-Phe.
D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000241:Adenosine / Q000494:pharmacology*; D000243:Adenosine Deaminase / Q000378:metabolism; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000097:blood*; D004357:Drug Synergism; D006801:Humans; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D013997:Time Factors
D010726:Phosphodiesterase Inhibitors; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D009240:N-Formylmethionine Leucyl-Phenylalanine; D000242:Cyclic AMP; D000243:Adenosine Deaminase; D000241:Adenosine